Randomized Placebo-controlled Trial of Rosuvastatin in HIV-Infected Subjects to Modulate Cardiovascular Risk and Inflammation

Trial Profile

Randomized Placebo-controlled Trial of Rosuvastatin in HIV-Infected Subjects to Modulate Cardiovascular Risk and Inflammation

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Jul 2017

At a glance

  • Drugs Rosuvastatin (Primary)
  • Indications Cardiovascular disorders; HIV infections; Metabolic syndrome
  • Focus Biomarker; Pharmacodynamics
  • Acronyms SATURN-HIV
  • Most Recent Events

    • 24 Jul 2017 Results of secondary analysis assessing effect of pericardial fat volume and density on markers of insulin resistance and inflammation published in the American Journal of Cardiology
    • 16 Feb 2017 Results assessing effect of statin on arginine metabolites; presented at the 24th Conference on Retroviruses and Opportunistic Infections
    • 16 Feb 2017 Results presented at the 24th Conference on Retroviruses and Opportunistic Infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top